Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Background:Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are targeted therapies designed to selectively block CDK4/6, crucial regulators of the cell cycle. These inhibitors play a pivotal role in restoring cell cycle control, particularly in breast cancer cases marked by abnormal CDK regulation, ultimately inhibiting uncontrolled cell division and tumor growth.Objectives:This analysis aimed to comprehensively examine adverse effects in CDK4/6 inhibitors using the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.Design:Disproportionality analysis was conducted to analyze the adverse event (AE) reports related to CDK4/6 inhibitor submitted to the FAERS database.Methods:We collected AE reports regarding palbociclib, ribociclib, abemaciclib, trilaciclib, and dalpiciclib submitted to the FAERS from 2015Q1 to 2023Q1. We used the system organ class and the Standardized MedDRA Query to perform a comprehensive search for AEs at the preferred term (PT) level, using case reports as our data source. After removing duplicate reports, we performed disproportionality analysis and sensitivity analysis to identify safety signals.Results:A total of 85,635 reports encompassing 280,211 AEs were extracted for analysis. Among 3681 scrutinized PTs, approximately 484 were detected as statistically significant signals associated with CDK4/6 inhibitors. It was noteworthy that palbociclib and ribociclib had comparable safety profiles, whereas abemaciclib exhibited distinctive safety patterns. Notably, our analysis found novel safety signals linked to CDK4/6 inhibitors, including nail-related disorders such as onychoclasis, nail disorder, and nail discoloration, and psychiatric concerns, including eating disorders and emotional disorder.Conclusion:Overall, the present study identified several new safety signals of CDK4/6 inhibitors, as well as differences among various drugs within the CDK4/6 category, through the use of the FDA FAERS, which deserve more careful monitoring in the clinic.Plain language summaryA study on the adverse effects of CDK4/6 inhibitorsIntroduction:An adverse event (AE) refers to any undesirable or harmful occurrence that happens to an individual during or after the use of a medical product or intervention. These events are typically reported to regulatory authorities, such as the Food and Drug Administration (FDA), to ensure the safety and effectiveness of medical products. The United States Food and Drug Administration Adverse Event Reporting System (FAERS) database plays a pivotal role in identifying these adverse events. Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a class of drugs used to treat certain types of cancer by inhibiting the growth and division of cancer cells. This study investigated the safety signals related to CDK4/6 inhibitors, including palbociclib, ribociclib, abemaciclib, and trilaciclib, by using the FAERS database.Methods:We collected AE reports associated with CDK4/6 inhibitors that were submitted to the FAERS database between the first quarter of 2015 and the first quarter of 2023. Reporting odds ratio (ROR) method was used identify signals of AEs.Results:85,635 AE reports were identified, approximately 484 AE terms were identified as positive signals. Palbociclib and ribociclib had similar safety profiles, while abemaciclib showed a unique pattern. Our analysis also revealed previously unreported AEs, including nail-related disorders such as onychoclasis, nail disorder and nail discolouration. Psychiatric concerns such as eating disorders and emotional disorder were also identified.Conclusion:We discovered important safety concerns related to CDK4/6 inhibitors. Some of these concerns were consistent with previous studies, while nail-related disorders, eating disorder and emotional disorder were new and not mentioned in the drug labels or existing literature. Our findings may help physicians and pharmacists to weigh the risks and benefits of using CDK4/6 inhibitors in clinical practice.

A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases

Safety and Patient-Reported Outcomes in Patients with Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer Treated with CDK4/6 Inhibitors in China: A Cross-Sectional Study.

Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study

First-line CDK4/6 inhibitor-based combinations for HR+/HER2-advanced breast cancer: A Bayesian network meta-analysis

Efficacy and Safety of Abemaciclib-Based Therapy Versus Tucidinostat-Based Therapy after Progression on Palbociclib in Patients with HR+HER2- Metastatic Breast Cancer

Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study.

Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

Real-world experience of abemaciclib for adjuvant and metastatic breast cancer

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)

Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness

An evaluation of palbociclib as a breast cancer treatment option: a current update

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study